絕佳品質 |
產品列表 |
Cat.# | Product | Benchmark | Indication | Application |
SIM0001 | InVivoSIM™ anti-human TNFα (Adalimumab Biosimilar) |
Adalimumab (Humira) |
類風濕性關節炎、乾癬性關節炎、僵直性脊椎炎、克隆氏症…等自體免疫疾病 |
TNFα neutralization FC、ELISA、IF IP、IHC、WB |
SIM0002 | InVivoSIM™ anti-human EGFR (Cetuximab Biosimilar) |
Cetuximab (Erbitux) | 治療具表皮生長因子受體表現型,RAS原生型之轉移性直腸結腸癌病人。 與放射線療法合併使用,治療局部晚期之口咽癌、下咽癌及喉癌病人。 與內含鉑金類之化學療法合併使用,治療復發及/或轉移性頭頸部鱗狀細胞癌病人。 |
EGFR blockade ELISA、FC |
SIM0003 | InVivoSIM™ anti-human PD-1 (Nivolumab Biosimilar) |
Nivolumab (opdivo) | 無法切除或轉移性黑色素瘤、非小細胞肺癌、腎細胞癌、頭頸部鱗狀細胞癌、典型何杰金氏淋巴瘤、泌尿道上皮癌、無法切除的晚期或復發性胃癌。 | Blocking of PD-1/PD-L signaling FC、IHC、WB |
SIM0004 | InVivoSIM™ anti-human CTLA-4 (Ipilimumab Biosimilar) |
Ipilimumab (Yervoy) | 黑色素細胞瘤、腎細胞癌、大腸直腸癌、肝細胞癌、非小細胞肺癌、間皮細胞瘤 | CTLA-4 neutralization FC、ELISA、WB |
SIM0005 | InVivoSIM™ anti-human HER2 (Trastuzumab Biosimilar) |
Trastuzumab (Herceptin) | 早期乳癌、轉移性乳癌、轉移性胃癌。 | FC、ELISA、IHC、WB |
SIM0006 | InVivoSIM™ anti-human TNFα (Infliximab Biosimilar) |
Infliximab (Remicade) | 克隆氏症、潰瘍性結腸炎 | TNFα neutralization FC、ELISA、WB |
SIM0007 | InVivoSIM™ anti-human VEGF (Bevacizumab Biosimilar) |
Bevacizumab (Avastin) | 轉移性大腸直腸癌、轉移性乳癌、惡性神經膠質瘤、晚期或轉移性或復發性非鱗狀非小細胞肺癌、復發性卵巢上皮細胞、輸卵管或原發性腹膜癌、持續性或復發性或轉移性之子宮頸癌。 | VEGF neutralization FC、ELISA、IP、WB |
SIM0008 | InVivoSIM™ anti-human CD20 (Rituximab Biosimilar) |
Rituximab (Mabthera) | 非何杰金氏淋巴瘤、濾泡型B細胞非何杰金氏淋巴瘤、瀰漫性大型B細胞非何杰金氏淋巴瘤、類風濕性關節炎、慢性淋巴球性白血病、肉芽腫性血管炎、顯微多發性血管炎。 | FC、ELISA、WB |
SIM0009 | InVivoSIM™ anti-human PD-L1 (Atezolizumab Biosimilar) |
Atezolizumab (Tecentriq) | 肝細胞癌、非小細胞肺癌、小細胞肺癌、泌尿道上皮癌、三陰性乳癌、黑色素細胞瘤。 | FC、WB |
SIM0010 | InVivoSIM™ anti-human PD-1 (Pembrolizumab Biosimilar) |
Pembrolizumab (Keytruda) |
黑色素瘤、晚期非小細胞肺癌、典型何杰金氏淋巴瘤、頭頸部鱗狀細胞癌、泌尿道上皮癌。 | Blocking of PD-1/PD-L signaling Functional assays |
SIM0011 | InVivoSIM™ anti-human C5 (Eculizumab Biosimilar) |
Eculizumab (Soliris C5補體抑制劑) |
陣發性夜間血紅素尿症患有溶血性貧血且需輸血或有栓塞的併發症;非典型溶血性尿毒症候群(限施於plasma therapy-resistant之病人)。 | Inhibition of the activation of C5 Functional assays ELISA、IP |
SIM0012 | InVivoSIM™ anti-human VEGFR-2 (Ramucirumab Biosimilar) |
Ramucirumab (Cyramza) | 晚期或轉移性胃腺癌、局部晚期或轉移性非小細胞肺癌、轉移性大腸直腸癌。 | Functional assays IHC、FC |
SIM0013 | InVivoSIM™ anti-human IL-17A (Secukinumab Biosimilar) |
Secukinumab | 斑塊性乾癬、乾癬性關節炎、僵直性脊椎炎。 | Functional assays ELISA、IF、IHC、FC |
SIM0014 | InVivoSIM™ anti-human IL-6R (Tocilizumab Biosimilar) |
Tocilizumab (Actemra) | 類風溼性關節炎、多關節幼年型慢性關節炎 | Functional assays ELISA |
SIM0015 | InVivoSIM™ anti-human LAG-3 (Relatlimab Biosimilar) |
Relatlimab (臨床上跟Opdivo合併使用) |
晚期轉移性大腸直腸癌 | ELISA |
SIM0016 | InVivoSIM™ anti-human IgE (Omalizumab Biosimilar) |
Omalizumab (Xolair) | 過敏性氣喘附加療法、慢性自發性蕁麻疹附加療法(CSU) | IgE neutralization FC、ELISA |
SIM0017 | InVivoSIM™ anti-human NGF (Tanezumab Biosimilar) |
Tanezumab | 廣泛性止痛藥 (申請適應症:關節炎) |
NGF neutralization ELISA |